Want to see IMNM full AI Analyst Report?
IMNM Stock Chart & Stats
$29.38
$0.20(0.91%)
At close: 4:00 PM EDT
$29.38
$0.20(0.91%)
Day’s Range― - ―
52-Week Range$13.53 - $30.06
Previous CloseN/A
Volume615.24K
Average Volume (3M)1.26M
Market Cap
$2.26B
Enterprise Value$1.88B
Total Cash (Recent Filing)$520.00M
Total Debt (Recent Filing)$4.59M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 16, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding118,003,110
10 Day Avg. Volume1,314,775
30 Day Avg. Volume1,262,720
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.69
Enterprise Value/Ebitda-7.50
Forecast
1Y Price Target
$35.36Price Target Upside20.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$363.64K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity CushionMinimal leverage reduces balance-sheet debt risk and preserves financial flexibility relative to a heavily indebted biotech. The substantial equity base provides a cushion for continued development spending and may improve the company’s ability to pursue strategic options over the next several quarters.
Improved BMS Asset EconomicsThe amended BMS agreement removes future milestone, royalty, and other payment obligations tied to key assets while transferring related patent ownership to Immunome. This can improve long-term economics and strategic control, although the transaction also uses cash and increases share count.
Targeted Oncology Discovery PlatformA focused approach to molecularly defined cancers gives Immunome a coherent scientific strategy and supports development of multiple targeted programs. Its discovery and protein-engineering capabilities, combined with internal pipeline advancement, provide a foundation for future partnering or clinical value creation.
Bears Say
Revenue Has Fallen To ZeroThe move to zero trailing-twelve-month revenue shows that Immunome currently lacks recurring commercial product sales or dependable operating revenue. This leaves near-term funding and progress dependent on pipeline events, partnerships, or financing rather than an established revenue base.
Severe And Worsening Cash BurnDeeply negative operating and free cash flow indicates that the company requires substantial resources to continue advancing its programs. Persistent burn can consume the existing balance-sheet cushion and increase reliance on future financing, transactions, or successful development milestones.
Loss-making, Transaction-driven ModelLarge ongoing losses combined with a revenue model centered on licensing and milestone payments make financial results highly variable. Without recurring product revenue, profitability depends on uncertain development and partnering outcomes while substantial R&D spending continues.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $13.53 and its highest was $30.06 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $2.26B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Nov 16, 2026 which is in 32 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Aug 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.136.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.6.
How many shares outstanding does Immunome have?
Immunome has 118,003,110 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went up 6.629%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.36 (20.37% Upside)
$35.36 (20.37% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 83%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 486.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.36%
12-Months-Change
Fundamentals
Return on Equity
-50.56%
Trailing 12-Months
Asset Growth
90.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunome
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Stock 12 Month Forecast
Average Price Target
$35.36
▲(20.37% Upside)
Technical Analysis
Ownership Overview
1.45% Insiders
35.03% Mutual Funds
<0.01% Other Institutional Investors
50.98% Public Companies and
Individual Investors